Risk of heart failure found with Gleevec

July 31, 2006

A study published in the July 23 issue of Nature Medicine found that patients with chronic myelogenous leukemia (CML) receiving imatinib (Gleevec, Novartis) are at increased risk for heart failure. Researchers found that the ABL enzyme that is turned off by imatinib is actually a necessary component in maintaining the health of cardiac muscle cells.

Risk of heart failure found with Gleevec

A study published in the July 23 issue of Nature Medicine found that patients with chronic myelogenous leukemia (CML) receiving imatinib (Gleevec, Novartis) are at increased risk for heart failure. Researchers found that the ABL enzyme that is turned off by imatinib is actually a necessary component in maintaining the health of cardiac muscle cells. Scientists called for larger studies to determine the exact risk and emphasized the importance of assessing left ventricular function in future clinical trials.

To see more Hot off the Press news articles, click here http://www.drugtopics.com/Hot+off+the+Press.

Related Content:

News